Program
cipargamin
Also written as “KAE609”, “Cipargamin” and “KAE609 (Cipargamin)”.
In Novartis's pipeline, PfATP4 inhibitor
. Its studies are mostly in Malaria · Malaria, Falciparum · Parasitemia, led by Novartis.
Furthest: phase 2, since Jan 30, 201210 company-led studies, 2 open or runningNext primary completion: Feb 4, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 102 open or running | phase 2since Jan 30, 2012 | Jan 30, 2012 | Feb 4, 2027phase 2 · NCT07811908 |
- Named in Novartis’s own pipeline as
KAE609 (cipargamin)
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 30, 2012First study: phase 2 study in MalariaFirst studyNCT01524341 · 27 enrolled · Thailand
- Apr 17, 2013Phase 2 study in MalariaNCT01836458 · 25 enrolled · Vietnam
- May 21, 2013Phase 2 study in ParasitemiaNCT01860989 · 11 enrolled · Thailand, Vietnam
- Jul 23, 2015Phase 1 study in Malaria, FalciparumNCT02543086 · 8 enrolled · Australia
- Oct 27, 2017Phase 2 study in MalariaNCT03334747 · 188 enrolled · Gabon, Ghana, Mali and more
- Mar 23, 2020Phase 1 study in MalariaNCT04321252 · 57 enrolled · Belgium
- Dec 1, 2020Phase 2 study in MalariaNCT04675931 · 254 enrolled · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more
- Feb 17, 2023Phase 2 study in MalariaNCT05750628 · 327 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
- Nov 14, 2025Phase 2 study in Malaria, FalciparumNCT07235033 · 60 enrolled · Côte d’Ivoire, Gabon, Kenya
- Sep 4, 2026Phase 2 study in Malaria, FalciparumNCT07811908 · 120 planned · Burkina Faso, Côte d’Ivoire, Gabon and more
Ahead
- Feb 4, 2027Primary completion: phase 2 study in Malaria, FalciparumNCT07811908
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“PfATP4 inhibitor”the company's pipeline, read by Claude · source
“P-type ATPase inhibitor”ChEMBL 37, by rule
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07811908Malaria, Falciparum · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Recruiting | Feb 4, 2027 | 120 |
| NCT07235033Malaria, Falciparum · Côte d’Ivoire, Gabon, Kenya | 2 | Completed | Mar 5, 2025 | 60 |
| NCT05750628Malaria · Burkina Faso, Côte d’Ivoire, Gabon and more | 2 | Recruiting | Jun 9, 2026 | 327 |
| NCT04675931Malaria · Burkina Faso, Côte d’Ivoire, Democratic Republic of the Congo and more | 2 | Completed | Jul 24, 2025 | 254 |
| NCT04321252Malaria · Belgium | 1 | Completed | Nov 10, 2020 | 57 |
| NCT03334747Malaria · Gabon, Ghana, Mali and more | 2 | Completed | Nov 23, 2019 | 188 |
| NCT02543086Malaria, Falciparum · Australia | 1 | Terminated | Sep 2015 | 8 |
| NCT01860989Parasitemia · Thailand, Vietnam | 2 | Completed | Aug 2014 | 11 |
| NCT01836458Malaria · Vietnam | 2 | Completed | Mar 2015 | 25 |
| NCT01524341Malaria · Thailand | 2 | Completed | Jun 2012 | 27 |
How it is read
Names in the registry
- “KAE609”, 11 entries
- “Cipargamin”, 1 entry
- “KAE609 (Cipargamin)”, 1 entry
Conditions, from the studies’ own filings
- Malaria, 5 studies
- Malaria, Falciparum, 4 studies
- Parasitemia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.